A Biomarker Development Trial of Satraplatin in Patients With mCRPC
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer.
Clinical Pearls
William K. Oh, MD, professor of medicine, hematology and medical oncology, urology, The Mount Sinai Hospital, discusses a biomarker development trial of satraplatin in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- Satraplatin is a next-generation chemotherapy drug that will not move forward in development
- It is known that there is a subset of patients with advanced CRPC that respond to platinum chemotherapy
- Blood- and tissue-based biomarkers are in development to predict the subset of patients that will respond
<<<
Capivasertib Improves PFS in PTEN-Deficient mHSPC
November 30th 2024Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.
Read More
